

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

185,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Pseudomonas Aeruginosa and Newer β -Lactamases: An Emerging Resistance Threat

Silpi Basak, Ruchita O. Attal and Monali N. Rajurkar
*Jawaharlal Nehru Medical College, Datta Meghe Institute of
 Medical Sciences, Wardha (M.S.)
 India*

1. Introduction

The discovery of penicillin, the Magic bullet in 1928 and its clinical use in 1941 led the people to think that mankind has won the war against microbes. With a short span of seventy years, antimicrobial discovery from Penicillin to Tigecycline, mankind is facing the problem with some hospital strains resistant to almost all antimicrobials, and is busy in writing the obituary for antimicrobials.

Infact, the rising trend of developing resistance to multiple antibiotics in microbes, leading to therapeutic failure is a serious problem of global magnitude. *P.aeruginosa*, Methicillin Resistant *Staphylococcus aureus* (MRSA), Vancomycin resistant Enterococci(VRE), Glycopeptide Intermediate *Staphylococcus aureus* (GISA), Glycopeptide Resistant *Staphylococcus aureus* (GRSA), *Acinetobacter baumani*, *Stenotrophomonas maltophilia* etc. need special attention as they are commonly isolated from Health Care Associated Infections(HAI) and belong to Multidrug resistant Organism (MDRO) i.e. they are resistant to one or more classes of antibiotics (Harrison & Lederberg, 1998). *P. aeruginosa* is responsible for 10-15% of nosocomial infections worldwide. The β -lactam group of antibiotics which include Penicillins, Cephalosporins, Monobactams and Carbapenems are mainly used to treat infections caused by Gram negative bacteria. The widespread use of antibiotics put tremendous selective pressure on bacteria which develop new mechanisms to escape the lethal action of the antibiotics. These infections are difficult to treat because of emergence of newer β -lactamases such as Extended Spectrum β -lactamases (ESBL), AmpC β -lactamases and Carbapenemases. The β -lactamases inactivate β -lactam antibiotics by cleaving the structural β -lactam ring. Failure to detect these enzymes producing strains has contributed to their uncontrolled spread in Health Care setup and therapeutic failure.

Major mechanisms causing resistance to the β -lactam antibiotics in *P.aeruginosa* are the production of β -lactamases, reduced outer membrane permeability and altered affinity of target Penicillin binding proteins. (Washington et al, 2006; Pitt, 1990).

1.1 Classification of β -lactamases

β -lactamase can be classified according to Functional or Bush Jacoby Mederious classification (Bush et al, 1995), into group 1, 2a, 2be, 2br, 2c, 2d, 2e, 2f and according to molecular or Ambler

classification (Ambler, 1980) into Ambler class A,B,C and D. Detection of β -lactamase production has been achieved in the past by measuring the production of penicilloic acid, which is produced when benzyl penicillin is hydrolysed. The acid production can be detected by acidometric method, iodometric method and chromogenic cephalosporin (nitrocephin) method (Miles & Amyes, 2008). The first plasmid mediated β -lactamase was described in early 1960. The TEM1 enzyme was named after the patient Temoniera from whom it was originally found in isolated strains of *E.coli*, (Medeiros, 1984) whereas β -lactamase SHV-1 (Sulphydryl variable) is chromosomally encoded in most isolates of *Klebsiella pneumoniae* but is usually plasmid mediated in *E.coli* (Tzouveleki, 1999).

1.1.1 Extended spectrum β -lactamases (ESBL)

ESBLs were first reported in 1983 in *Klebsiella pneumoniae* from Germany. Typically ESBLs are mutant plasmid mediated β -lactamases derived from older broad-spectrum β -lactamases. The mutations alter the amino acid configuration around active site of β -lactamases (Thomson, 2001). The first ESBL to be described in 1983 was actually TEM3 (Sougakoff et al, 1980) and now over 130 additional TEMs have been isolated. ESBLs have an extended substrate profile that cause hydrolysis of cephalosporins, penicillins and aztreonam and are inhibited by β -lactamase inhibitors, such as clavulanate, tazobactam and sulbactam. ESBLs are commonly produced by *Klebsiella* species and *Escherichia coli*; but also occur in other Gram negative bacteria, including *Enterobacter*, *Salmonella*, *Proteus*, *Serratia marcescens*, *Pseudomonas aeruginosa*, *Burkholderia*, *Acinetobacter* species, etc.

1.1.2 AmpC β -lactamases

Molecular class C or AmpC primarily hydrolyses cepheems (cephalosporins and cephamycins) but also hydrolyze penicillins and aztreonam. These enzymes are resistant to the currently available β -lactamase inhibitors such as clavulanate, tazobactam and sulbactam (Philippon et al, 2002). With rare exceptions, the hydrolysis of cephamycins, such as cefotetan and cefoxitin, is a property that can help to distinguish AmpCs from ESBLs. Genes encoding inducible chromosomal AmpC β -lactamases are part of the genomes of many Gram negative bacteria specially *P.aeruginosa*. High level production of AmpC may cause resistance to the first, second and third-generation cephalosporins and cephamycins, penicillins and β -lactamase inhibitor combination. Higher level AmpC production may occur as a consequence of mutation or when the organism is exposed to an inducing agent. Cephamycins (e.g. cefoxitin and cefotetan), ampicillin, and carbapenem are good inducer (Moland et al, 2008). AmpC β -lactamases producing organisms are on rise and leads to therapeutic failure if 3rd Generation cephalosporins are given empirically or not tested in the laboratory for AmpC β -lactamases production (Basak et al, 2009). The chromosomally mediated AmpC β -lactamases are only inducible.

1.1.3 Carbapenemases

These include β -lactamases which cause carbapenem hydrolysis, with elevated carbapenem MICs and they belonged to molecular classes A, B and D. Molecular classes A, C and D include the β -lactamases with serine at their active site, whereas class B β -lactamases are all metalloenzymes with an active site zinc (Queenan & Bush, 2007).

Metallobetalactamases – They belong to molecular class B β -lactamases, and have 3 characteristics –

1. Hydrolyze carbapenems
2. Resistant to clinically used β -lactamase inhibitors and
3. Inhibited by EDTA, a metal ion chelator.

Other MBL inhibitors used are 2-mercaptoethanol, sodium mercapto acetic acid (SMA), 2-mercaptopropionic acid, copper chloride and ferric chloride (Arkawa et al, 2000). MBLs have a broad substrate spectrum and in addition to carbapenems, they can hydrolyze cephalosporin and penicillins but cannot hydrolyse aztreonam. Interestingly, not all of the MBLs readily hydrolyze nitrocefin. The first MBL detected were chromosomally encoded and was detected in *Bacillus cereus* (Lim et al, 1988). Since then there has been a dramatic increase in detection and spread of acquired or transferable families of these MBLs. There are 5 major families of acquired MBLs (IMP, VIM, SPM, GIM and SIM) (Toleman et al, 2007). In 1990, IMP-1, the 1st MBL encoded on plasmid, was discovered in Japan (Watanabe et al, 1991). The MBLs are located on integrons and are incorporated as gene cassettes. When these integrons become associated with plasmids or transposons, transfer between bacteria is facilitated.

Classification of MBLS

MBLS are classified into 3 subclasses—B1, B2 and B3. Subclass B1 and B3 are divided by amino acid homology, bind 2 zinc atoms for optimal hydrolysis and have broad hydrolysis spectrum. Subclass B2 are inhibited when a second zinc atom is bound and preferentially hydrolyse carbapenem (Free et al, 2005).

Molecular class A carbapenemase – Class A serine carbapenemases belong to functional group 2f include chromosomally encoded NMC(not metalloenzyme carbapenemase), IMI (Imipenem hydrolyzing β -lactamase) and SME(*Serratia marcescens* enzyme) and plasmid mediated KPC (*Klebsiella pneumoniae* carbapenemase) and GES/IBC(integron borne cephalosporinase) (Queenan & Bush, 2007). All have the ability to hydrolyse carbapenems, cephalosporins, penicillins and aztreonam and all are inhibited by clavulanate and tazobactam. The chromosomal class A carbapenemase are infrequently found and can be induced by imipenem and cefoxitin. The KPC (*Klebsiella pneumoniae* carbapenemase) producing strains are found in *Klebsiella pneumoniae*, *Enterobacter* species, *Salmonella* species and other *Enterobacteriaceae* (Hossain et al, 2004; Miriagou et al, 2003).

Class D Serine carbapenemases: The OXA (Oxacillin hydrolysing) β -lactamase with carbapenemase activity was detected by Patow et al in 1993 and the enzyme was purified from *Acinetobacter baumannii* (Queenan & Bush, 2007). They have been also found in *Enterobacteriaceae* and *P. aeruginosa* and were described as penicillinase capable of hydrolyzing oxacillin and cloxacillin (Bush & Sykes, 1987; Naas & Nordmann, 1999). They were poorly inhibited by clavulanic acid and EDTA and were designated as ARI-1 (*Acinetobacter* Resistant to Imipenem) and reside on large plasmid. The OXA carbapenemases have hydrolytic activity against penicillins, some cephalosporins and imipenem. The widespread use of reserved antibiotics such as β -lactam / β -lactamases inhibitor combinations, monobactams and carbapenem has caused persistent exposure of bacterial strains to a multitude of β -lactam leading to overproduction of β -lactamases (Goossens et al, 2004; Manoharan et al, 2010; Lee et al, 2003). Consequently the emergence of

carbapenem resistance is a world-wide public health concern since carbapenems are used as last resort to treat serious infections caused by ESBL producing organisms. Approximately 40% strains of *P.aeruginosa* are resistant to anti-pseudomonal drugs including carbapenems. Therefore, early detection of ESBL, AmpC β -lactamase & MBL producing *P. aeruginosa* strains is of crucial importance for prevention of their inter and intra hospital dissemination.

1.2 Aims and objectives

The present study was undertaken with the aim to study *Pseudomonas aeruginosa* with special reference to β -lactamase production isolated in the Department of Microbiology, Jawaharlal Nehru Medical College, Wardha (M. S.), India.

1.2.1 To fulfill the aim the following objectives were taken

- To study the prevalence of Extended Spectrum β -lactamases (ESBL), Amp C β -lactamases, Metallobetalactamases (MBL) producing *Pseudomonas aeruginosa* strains, isolated from different clinical samples of patients attending the Hospital
- To study the antibiotic susceptibility profile of Extended Spectrum β -lactamases (ESBL), Amp C β -lactamases and Metallobetalactamases (MBL) producing *Pseudomonas aeruginosa* strains isolated.

2. Material and methods

The study was conducted from 1st September 2008 to August 2010 (2 year period). A total number of 250 *P.aeruginosa* strains were isolated from different clinical samples e.g. urine, pus and wound swab, blood, catheter tips, endotracheal tube secretions, different body fluids etc. received from indoor as well as outdoor patients departments (IPD &OPD) of our hospital, which is a tertiary care hospital in a rural set-up. *P.aeruginosa* strains were characterized according to conventional identification tests. *P.aeruginosa* ATCC 27853 were used as positive control for all conventional tests. All antibiotic disks and culture media used in the study were procured from HiMedia laboratories Pvt. Limited, India. Ethylene Diamine Tetraacetic acid (EDTA) and 3-amino phenylboronic acid (APB) were procured from Sigma-Aldrich.

2.1 Antibiotic susceptibility testing

All 250 *P.aeruginosa* strains were subjected to antibiotic susceptibility testing to different antimicrobial agents using Mueller-Hinton agar plates by Kirby-Bauer disk diffusion method according to CLSI guidelines (CLSI Document M2-A9, 2006). Using sterile swab, lawn culture of the test strain (turbidity adjusted to 0.5 McFarland standard) was made on Mueller Hinton Agar plate. With all aseptic precaution, the antibiotic disks were put on that inoculated plate. Six antibiotic disks were put on a 90mm diameter plate. The antibiotic sensitivity tests were put for aminoglycosides such as amikacin (Ak-30 μ g), netilmicin (Nt-30 μ g); cephalosporin such as ceftazidime(Ca-30 μ g), cefepime(Cpm-30 μ g); fluoroquinolones i.e. ciprofloxacin(Cf-5 μ g); monobactams i.e. aztreonam (Ao-30 μ g); carbapenems such as imipenem(I-10 μ g), meropenem(Mr-10 μ g); piperacillin/tazobactam (Pt-100/10 μ g), ceftazidime/clavulanic acid (Cac-30 μ g / 10 μ g) and polymyxin B (Pb-300 μ g) etc. (Fig. 1)




Fig. 1. Antibiotic susceptibility test.

Detection of newer β -lactamases

Though several methods both phenotypic and genotypic have been described for detection of newer β -lactamases, we restricted our study only to phenotypic methods. There is no CLSI guideline given for detection of ESBL, AmpC β -lactamases and MBL producing *P. aeruginosa*.

2.1.1 Detection of extended spectrum β -lactamases (ESBL)

Screening test: ESBL production was detected by reduced susceptibility to Ceftazidime, Cefotaxime.

Confirmatory tests: As per Clinical and Laboratory Standard Institute (CLSI) guidelines for Enterobacteriaceae (Waynepa CLSI, 2008; Storenburg, 2003), we used the same combined disk method as confirmatory test for *Pseudomonas aeruginosa* also, as the principle remains the same.

1. **Combined Disk Method** (Carter et al, 2000)

Broth cultures of test strains were adjusted to McFarland 0.5 standard and used to inoculate Mueller Hinton agar plates with a sterile swab. Commercialized disks containing ceftazidime (Ca) 30 μ g and ceftazidime plus clavulanate (Cac) 30 μ g plus 10 μ g respectively were used in this method. An increase in diameter of ≥ 5 mm with ceftazidime plus clavulanate (Cac) disk as compared to ceftazidime (Ca) disk alone was considered positive for ESBL detection. All 250 *P. aeruginosa* strains were also tested using piperacillin (Pc) 100 μ g & piperacillin-tazobactam (Pt) 100 μ g plus 10 μ g respectively in combination.

2. **E test ESBL strip** (Washington et al, 2006)

The E-test ESBL confirmatory test strips are based on the CLSI dilution method. The strip has concentration gradients of ceftazidime (TZ) 0.5 to 32 μ g/ml on one half and ceftazidime 0.064 to 4 μ g/ml plus 4 μ g/ml clavulanic acid (TZL) on another half. The ESBL E-test was performed and interpreted using test strains and Quality Control strains according to the manufacturer's instructions. In this method lawn culture of test strain was done on a Mueller Hinton agar plate. With a sterile forceps the ESBL E-test strip was placed onto the inoculated plate. After overnight incubation at 37°C, the zone of inhibition was read from two halves of the strip. MIC ratio of ceftazidime/ceftazidime clavulanic acid (TZ/TZL) ≥ 8 or deformation of ellipse or phantom zone present was considered as positive for ESBL production.

2.1.2 Detection of Amp C β -lactamases

For detection of AmpC class of β -lactamases, no satisfactory technique has been established till date as per CLSI guidelines. Induction of C β -lactamase synthesis was Amp based on the disc approximation assay using several inducer substrate combinations.

Screening test: Several inducer/substrate combinations disks like Cefoxitin/Piperacillin, Imipenem/Ceftazidime, Imipenem/Cefotaxime, Imipenem/Cefoxitin, Imipenem/Piperacillin-Tazobactam were used as described by Dunne and Hardin et al. Imipenem and cefoxitin were used as inducers of AmpC β -lactamases (Dunne & Hardin, 2005).

Interpretation: Strains were considered inducible if a positive test was obtained with any of the inducer/substrate combinations. A test was considered positive if the zone of inhibition was reduced by ≥ 2 mm on the induced side of the substrate disc or even blunting of substrate zone of inhibition adjacent to inducer disc. Also, if the zone of inhibition produced by ceftazidime/ceftazidime-clavulanic acid (Cac) disk was ≥ 2 mm less than the zone produced by a ceftazidime (Ca) disk, the strain was considered to be inducible Amp C positive. Similarly, same criteria was used for piperacillin & piperacillin/tazobactam (Pc/Pt) disks.

Confirmatory test: Disk potentiation (DP) test and Double disk synergy test (DDST) using 3-aminophenylboronic acid (APB) (100mg/ml dissolved in DMSO) (Yagi et al, 2005). An increase in zone size of ≥ 5 mm around the Ceftazidime- APB disk compared to ceftazidime only disk was recorded as a positive result for disk potentiation test. In DDST, the presence of change in the shape of growth inhibitory zone around ceftazidime or cefotaxime disk through the interaction with the 3- Aminophenyl boronic acid containing disk was interpreted as positive for AmpC production.

2.1.3 Detection of metallo β -lactamases (MBL)

All imipenem resistant strains were screened for Carbapenemase activity by Classical Hodge Test and Modified Hodge Test (MHT) (Lee et al, 2001a; 2003b). *Pseudomonas aeruginosa* strains which were positive by Classical Hodge Test (IHT) and Modified Hodge Test (MHT) were tested for metallo β -lactamase (MBL) production by Imipenem/EDTA double disk synergy test (Lee et al, 2001) and disk potentiation test or imipenem-EDTA combined disk test (Yong et al, 2002) using Di-potassium EDTA (10 μ l of 0.5 M).

Imipenem-EDTA double disk synergy test (DDST) (Lee et al, 2001)

The IMP-EDTA double disk synergy test was performed for detection of metallo β -lactamases. Test strains i.e. *Pseudomonas aeruginosa* (turbidity adjusted to 0.5 McFarland standard) were inoculated on to Mueller Hinton agar plate. After drying, a 10 μ g Imipenem disk and a blank sterile filter paper disk (6mm in diameter, Whatman filter paper no.2) were placed 10mm apart from edge to edge. 10 μ l of 50mM zinc sulfate solution was added to the 10 μ g imipenem disk. Then, 10 μ l of 0.5 M EDTA (Sigma, USA) solution was applied to the blank filter paper disk. As disodium-EDTA is difficult to be solubilised in sterile water, we had used dipotassium-EDTA which is easily soluble in sterile water. Enhancement of the zone of inhibition towards the EDTA disk was interpreted as a positive result.

Disk Potentiation test or Imipenem-EDTA combined disk test (Young et al, 2002)

The test was performed for detection of metallo β -lactamases. Test strains (turbidity adjusted to 0.5 McFarland standard) were inoculated on to Mueller Hinton agar plate. Two

imipenem disk (10 μ g) were placed on the plate wide apart and 10 μ l of 50mM zinc sulphate solution was added to each of the imipenem disks. Then 10 μ l of 0.5 M EDTA solution was added to one of the disk to obtain the desired concentration. The inhibition zones of the imipenem and imipenem-EDTA disks were compared after 16-18 hours of incubation at 35°C. If the increase in inhibition zone with the Imipenem and EDTA disk was ≥ 7 mm than the imipenem disk alone, it was considered as MBL positive.

The MBL producing strains were further confirmed by using MBL – E test strip (AB bioMerieux) (Walsh et al, 2002).

MIC ratio of Imipenem /Imipenem-EDTA (IP/IPI) of ≥ 8 or deformations of ellipse or phantom zone indicate MBL production by MBL E-test.

2.2 Observations and results

Maximum 204(81.6%) P.aeruginosa strains were isolated from Indoor Patient Department (IPD). No newer β -lactamase producing strains were isolated from patients attending Out Patient Department




Fig. 2. Isolation of Pseudomonas aeruginosa strains from OPD, IPD and ICU patients.

Fig. 3 shows 165 (66%) P.aeruginosa strains were ESBL, AmpC β -lactamases and MBL producers.




Fig. 3. Prevalence of newer β -lactamases producing P. aeruginosa strains (n=250).

P.aeruginosa	ESBL		AmpC		MBL	
	No.	Percentage	No.	Percentage	No.	Percentage
n=250	100	40	105	42	28	11.2

Table 1. Prevalence of ESBL, AmpC β -lactamase and MBL producing *P. aeruginosa* (n=250)

Amongst the 100 ESBL (Fig. 4) and 105 Amp C β -lactamase producers (Fig. 5 & 6), 68 (27.2%) *P. aeruginosa* strains had produced both ESBL as well as AmpC β -lactamases. 28 (11.2%) *P. aeruginosa* strains were Metallobetalactamase (MBL) producers.



Fig. 4. Detection of ESBL(Combined disk method)

Detection of AmpC β -lactamases (Figure 5&6)



Fig. 5. Inducer-substrate combination disk test.

Fig. 7 shows amongst 100 ESBL and 105 AmpC β -lactamase producers 68 (41.2%) strains had produced both ESBL as well as AmpC β -lactamases. There was no strain which produced all the 3 types of β -lactamases. Similarly, no strain produced ESBL or AmpC β -lactamase along with MBL.



Fig. 6. DDST & DP test using 3-Aminophenyl-boronic acid (3-APB).




Fig. 7. Incidence of different newer β -lactamases producing *P.aeruginosa* strains(n=165)

Table 2 shows that out of 250 *P. aeruginosa* strains studied, 31 (12.4 %)were imipenem resistant and 28 (11.2 %) were metallo β lactamase (MBL) producers. 31 imipenem resistant strains were screened for carbapenem hydrolysis by Classical Hodge test (HT) & modified Hodge test (MHT). Amongst these 31 imipenem resistant *P. aeruginosa* strains, 28 (90.3%) were positive for Classical Hodge test (HT) & modified Hodge test (MHT) for carbapenem hydrolysis and these 28 strains were also positive for metallo β lactamase (MBL) production by Double disk synergy test (DDST) and disk potentiation test (DP).

Imipenem resistant <i>P. aeruginosa</i>	Screening test for carbapenem hydrolysis		Confirmatory test for MBL		
	Classical Hodge test	Modified Hodge test	Double disk synergy test	Disk potentiation test	MBL E-test
n = 31	28	28	28	28	28

Table 2. Prevalence of MBL producing *P. aeruginosa* (n =250)

These 28 strains were also confirmed for metalloβ-lactamase (MBL) production by using MBL E-test strip (AB bioMérieux). MBL E-test (Fig. 9) shows MIC ratio of imipenem IP/ imipenem-EDTA IPI for test strain *P. aeruginosa* as 16/1 i.e. 16 and MBL E-test positive. The phantom zone shown in Fig. 9 is another criteria for MBL E-test positivity. MBL E-tests done for those 28 *P. aeruginosa* strains showed that the MIC ratio of imipenem / imipenem-EDTA i.e. IP/IPI were > 8 such as 16/1 for 9 strains, 24/1.5 for 3 strains, 32/1 for 5 strains, 48/1 for 8 strains, 64/1 for 2 strains and 128/1 for 1 strain.

Confirmation of MBL by E-test : Figure 8 & 9




Fig. 8. Quality control: *P. aeruginosa* ATCC 27853 (MBL E test negative).




Fig. 9. MBL E-test (positive).

Fig. 10 shows from ICU 6 (14.3%) strains produced both ESBL and AmpC β -lactamases whereas 9(21.4%) strains produced MBL.





Fig. 10. Isolation of different β -lactamases producing *P. aeruginosa* strains from ICU.



*others include throat swab, vaginal swab, ear swab, bronchial wash, tip of catheter & drain fluid.

Fig. 11. Isolation of β -lactamases producing *P.aeruginosa* strains from different clinical specimens.

In the present study, maximum *P.aeruginosa* strains isolated from pus and wound swab, 73 (29.2%) followed by 60(24%) from urine. The fig. 11 shows 26(49%) *P.aeruginosa* strains isolated from sputum sample were both ESBL and AmpC β -lactamase producer. 50% *P.aeruginosa* strains isolated from endotracheal tube secretions were MBL producers. Though no MBL producing strains were isolated from blood culture.

Fig. 12 shows maximum 36.2% strains isolated from Medicine ward produced both ESBL and AmpC β -lactamase. From surgery ward maximum 10(35.7%) strains were MBL producers. No MBL producing *P.aeruginosa* strains were isolated from Neonatal Intensive Care Unit(NICU) and 3(20%) strains were only ESBL producers.




Fig. 12. Isolation of β -lactamases producing *P. aeruginosa* strains from different clinical specialities

Fig. 13 shows that *P.aeruginosa* strains showed a high degree of resistance to cefepime (90.4%), ceftazidime(91.6%) and ceftazidime(67.2%). However effective antimicrobial agents were found to be polymyxin B (100%), Imipenem(87.6%) and piperacillin-tazobactam (86%) sensitive.




Fig. 13. Antibiotic susceptibility profile of *P. aeruginosa* strains (n=250)

Fig. 14 shows most effective antimicrobial agent against ESBL andAmpC β -lactamase producing *P.aeruginosa* strains were Imipenem(100%) and Polymyxin-B(100%). However, sensitivity of ESBL and AmpC β -lactamase producers to piperacillin-tazobactam were 100% and 82.8% respectively.




Fig. 14. Antibiotic susceptibility profile of ESBL & Amp C β -lactamases producing *P.aeruginosa* strains

Fig.15 shows all(100%) MBL positive isolates were sensitive to polymyxin-B. 1(3.7%) each MBL producing strain was sensitive to Amikacin and Netilmicin respectively. But no MBL producing strain was susceptible to Aztreonam.




Fig. 15. Antibiotic susceptibility profile of MBL & non-MBL *P. aeruginosa* strains

2.3 Discussion

Pseudomonas aeruginosa is one of the most important microorganisms which causes problems clinically as a result of its high resistance to antimicrobial agents and is therefore a particularly dangerous & dreaded bug. Despite the discovery of ESBL, Amp C β -lactamases and MBL at least a decade ago, there remains a low level of awareness of their importance and many clinical laboratories have problems in detecting ESBL& Amp C β -lactamases. Failure to detect these enzymes has contributed to their uncontrolled spread and commonly to therapeutic failures.

Detection problems arise especially with organisms that produce an inducible Amp C β -lactamases, as clavulanate can induce high level production of Amp C, which may obscure recognition of ESBLs (Moland et al, 2008). According to Clinical & Laboratory Standards (CLSI) interpretive definitions, ESBLs do not always increase MICs to levels characterized as resistant (Livermore, 2002). Not only that ESBL producing organisms may give false sensitive zones in routine disk diffusion test. The number of infections caused by Amp C β -lactamases producing *P. aeruginosa* is on rise and poses a threat to patients due to therapeutic failure if they remain undetected (Arora & Bal, 2005). Metallobetalactamase (MBL) producing *P. aeruginosa* is an emerging threat and a cause of concern for treating physicians as it can hydrolyze carbapenems which are given as a last resort to the patient having infection with ESBL and AmpC β -lactamase producing *P. aeruginosa*. The MBLs have become more notorious as therapeutically available inhibitors are not available and for their potential for rapid and generalized dissemination to different other Gram negative bacilli. Hence, accurate identification of MBL producing strains are very urgently needed. Though PCR gives specific and accurate results, its use is limited to few laboratories because of its high cost and different types of ESBLs, AmpC β -lactamases and metallobetalactamases (MBLs) present worldwide (Moland et al, 2008b).

In the present study 81.6% *P. aeruginosa* strains were isolated from IPD patients. Algun et al from Turkey in 2004 reported isolation of *P. aeruginosa* 61% from IPD patients. Basak et al in 2009 reported 89.3% isolation from IPD and 10.7% from ICU from our hospital.

In the present study, co-existence of MBL producing *P. aeruginosa* was not observed along with ESBL & Amp C producers. Saha et al in 2010 reported 86% strains producing both MBL and Amp C β -lactamases while only one strain was observed to produce both ESBL and MBL. In the present study 68(27.2%) strains were both ESBL & Amp C β -lactamases producers amongst 250 *P. aeruginosa* strains studied.

6(2.2%) MBL producing strains were isolated from Medicine ICU. Sarkar et al in 2006 reported 36.4% of imipenem resistance in nosocomially infected patients with *P. aeruginosa*. In present study, we found 15 (35.7%) *P. aeruginosa* from NICU and all were from blood cultures of neonates and all were imipenem sensitive. Only 3 (20%) of these were found to be positive for ESBL production. Arkawa et al, 2000 recommended testing ceftazidime-resistant isolates for MBL production because in their study some MBL producing Gram negative bacilli were inhibited by low concentration of imipenem and they were difficult to detect. But Lee et al, 2001 reported that in their study, not a single MBL-producing isolates were detected among imipenem susceptible isolates.

In Japan, Sugino et al, 2001 used only carbapenem non-susceptible isolates for screening of MBL. Hence we also used carbapenem resistant isolates for detection of MBL. Though Arkawa et al, 2000 and other authors have done DDST & Disc potentiation test with ceftazidime and EDTA, in our study we used imipenem and EDTA for DDST & Disc potentiation test. As in our study, even in non MBL producing *P. aeruginosa* strains, the ceftazidime resistance was quite high (69.8%). The MBL producing strains may also have another ceftazidime resistance mechanism (Lee et al, 2003b). With such type of strains, DDSTs using an imipenem disc can show positive results for MBL but a ceftazidime disc can not; just as a cefepime disc but not a ceftazidime disc can detect extended spectrum β -lactamase (ESBL) production in Amp-C β -lactamase producing strains.

Though Franklin et al, 2006 have reported that 87% of their MBL producing Enterobacteriaceae isolates had >30mm of zone with aztreonam, we did not find any MBL producing *P.aeruginosa* strain to be susceptible to aztreonam. This can only be explained by the fact that there are presence of some other mechanisms for aztreonam resistance in *P. aeruginosa* strains isolated.

Aggarwal et al in 2008 found that polymyxin B was the most effective antibiotic recording 0% resistance, similar was the finding of our study. In our study we found 67.2% resistance against ceftazidime which was quite high and correlated well with the study of Behra et al in 2008 who had reported 70% resistance to ceftazidime.

3. Conclusion

Microbial drug resistance is now a global problem due to newer β -lactamases produced by Gram-negative bacteria including *Pseudomonas aeruginosa*. E-test and Polymerase chain reaction (PCR) can be used for accurate detection of newer β -lactamases, but both are costly and require expertise and cannot be done routinely.

Hence to conclude, for detection of ESBL, combined disk method using piperacillin/piperacillin-tazobactam (Pc/Pt), for detection of Amp C β -lactamases confirmatory Disk potentiation test using 3-aminophenylboronic acid and for detection of MBL producing *P. aeruginosa* disk potentiation test using imipenem-EDTA should be done by all clinical Microbiology laboratories to prevent its dissemination and also for a good therapeutic outcome as these tests are economical, easy to perform and quite specific.

4. Acknowledgment

The author highly acknowledge the Datta Meghe Institute of Medical Sciences, Deemed to be University for funding this project.

5. References


- Aggarwal G., Lodhi R B., Kamalakar U P., Khadase R K., Jalgaokar S V. (2008). Study of metallo β -lactamases production in clinical isolates of *P. aeruginosa*. *Indian J Med Microbiol.* Vol 26 No.4 pp. (349-351).
- Algun U., Arisoy A., Gunduz T., Ozbakkaloglu B. (2004). The resistance of *Pseudomonas aeruginosa* strains to Fluoroquinolone group of antibiotics. *Indian J Med Microbiol.* Vol 22 No.2 pp. (112-114).
- Ambler, R. P. (1980). The structure of β -lactamases. *Phil. Trans. R.Soc. Lond. B. Biol. Sci.* Vol 289 pp. (321-331).
- Arkawa Y., Shibata N., Shibayama K., Kurokawa H., Yogi T. Fusiwara H, et al. (2000). Convenient test for screening metallo β -lactamases producing gram-negative bacteria using thiol compounds. *J Clin Microbiol* Vol 38 pp. (40 - 43).
- Arora S., Bal M. (2005). Amp C β -lactamases producing bacterial isolates from Kolkata hospital. *Indian J Med Res.* Vol 122 pp. (224-233).
- Basak S., Khodke M., Bose S., Mallick SK. (2009). Inducible AmpC Beta-Lactamase Producing *Pseudomonas Aeruginosa* Isolated In a rural Hospital of Central India. *Journal of Clinical and Diagnostic Research.* Vol 3 pp. (1921-1927).

- Behra B., Mathur P., Das A., Kapil A., Sharma V. (2008). An evaluation of four different phenotypic techniques for detection of metalloβ-lactamases producing *Pseudomonas aeruginosa*. *Indian J Med Microbiol* Vol 26 No.3 pp. (233-237).
- Bush, K., and R. B. Sykes. (1987). Characterization and epidemiology of β-lactamases. Elsevier Science Publishers BV, Philadelphia, PA.
- Bush K., Jacoby GA., Medeiros A. (1995). A functional classification scheme for beta lactamase and its correlation with molecular structure. *Antimicrob Agents Chemother.* Vol 39 pp. (1211-1233).
- Carter MW., Oakton KJ., Warner M., Livermore DM. (2000). Detection of extended spectrum beta lactamases in *Klebsiellae* with the Oxoid combination disk method. *J Clin Microbiol* . Vol 38 pp. (4228-4232).
- Clinical and Laboratory Standards Institute. (2006). *Performance standards for antimicrobial disk tests; Approved Standards, 9th ed. CLSI Document M2- A9*, Vol. 26 No 1. Wayne PA.
- Dunne WM. and Hardin DJ. (2005). Use of Several Inducer and substrate Antibiotic Combinations in a Disk Approximation Assay format to screen for AmpC induction in patient isolates of *Pseudomonas aeruginosa*, *Enterobacter* spp, *Citrobacter* spp and *Serratia* spp. *J Clin Microbiol* . Vol 15 pp. (5945-5949).
- Franklin C., Liolios L., Peleg AY. (2006). Phenotypic Detection of carbapenem susceptible Metalloβ-lactamase producing Gram-negative bacilli in the clinical laboratory. *J of Clin Microbiol.* Vol 44 No.9 pp. (3139-3144).
- Free J.M., Galleni M., Bush K., Didiberg O. (2005). Is it necessary to change the classification of β-lactamases? *J. Antimicrob. Chemother.* Vol 55 pp. (1051-1053).
- Goossens H., Malhotra Kumar S., Eraksoy H., Unal S., Grabein B., Masterton R. *et al.* (2004). MYSTIC study group: Results of two world wide surveys into physician awareness and perceptions of extended spectrum spectrum beta lactamases. *Clin Microbiol Infect.* Vol 10 pp. (760-762).
- Hossain, A., Ferraro MJ., Pino RM., Dew III RB., Moland ES., Lockhart TJ., Thomson KS., Goering RV., Hanson ND. (2004). Plasmid mediated carbapenem-hydrolyzing enzyme KPC-2 in an *Enterobacter* sp. *Antimicrob. AgentsChemother.* Vol 48 pp. (4438-4440).
- I.O.M.(1998) eds. Harrison, P.F. & Lederberg J. pp. (8-74), National Academy Press Washington, DC.
- Lee K., Chong Y., Shin H B., Kim Y A., Yong D., Yum J H. (2001). Modified Hodge and EDTA disk synergy test to screen metalloβ-lactamases producing strains of *Pseudomonas* spp and *Acinetobacter* spp. *Clin Microbiol Infect.* Vol 7 pp. (88 - 91).
- Lee K., Lim Y S., Yong D., Yum J H., Chong Y. (2003). Evaluation of Hodge test and imipenem-EDTA double disk synergy test for differentiation of metalloβ-lactamases producing clinical isolates of *Pseudomonas* spp and *Acinetobacter* spp. *J Clin Microbiol.* Vol 4 pp. (4623 - 4629).
- Lee K., Lee WG., Uh Y., Ha GY., Cho J., Chong Y. (2003). VIM and IMP - type metalloβ-lactamase producing *Pseudomonas* spp. and *Acinetobacter* spp in Korean hospitals. *Emerg Infect Dis.* Vol 9 pp. (868-871).
- Lim HM., Pene J.J., Shaw RW. (1988). Cloning, nucleotide sequence and expression of the *Bacillus cereus* 5/B/6 β-lactamase II structural gene. *J. Bacteriol.* Vol 170 pp. (2873-2878).

- Livermore DM. (2002). Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. *J Antimicrob Chemother.* Vol 49 pp. (289-300).
- Manoharan A., Chatterjee S., Mathai D., SARI Study Group. (2010). Detection and Characterization of metallo β lactamases producing *Pseudomonas aeruginosa*. *Indian J Med Microbiol.* Vol 28 No.3 pp. (241-243).
- Me deiros A A. (1984). β -lactamases *Br. Med Bull.* Vol 40 pp. (18-27).
- Miles RS., Amyes SGB. 2008 Laboratory control of antimicrobial therapy chapter 8 In *Mackie & McCartney's Practical Medical Microbiology*, 14th ed, JG Collee, AG Fraser, BP Marmion, A Simmons, Editors, pp. (151-178) Churchill Livingstone, ISBN: 978-81-312-0393-4, Indian Reprints.
- Miriagou, V., Tzouveleakis L. S., Rossiter S., Tzelepi E., Angulo F.J., Whichard J.M. (2003). Imipenem resistance in a *Salmonella* clinical strain due to plasmid-mediated class A carbapenemase KPC-2. *Antimicrob. Agents Chemother.* Vol 47 pp. (1297-1300).
- Moland E S., Kim S., Hong S G., Keneeth & Thomson. (2008). Newer β -lactamases: Clinical & Laboratory Implication Part 1. *Clinical Microbiology Newsletter*, Vol 30 No.10 pp. (71-78).
- Naas, T., P. Nordmann. (1999). OXA-type β -lactamases. *Curr. Pharm.Des.* Vol 5 pp. (865-879).
- Philippon A., Arlet G., Jacoby GA. (2002). Plasmid-determined Amp C type β -lactamases. *Antimicrob Agents Chemother.* Vol 46 pp. (1-11).
- Pitt T L. (1990). *Pseudomonas*: vol 2 chapter 2.12. *Topley & Wilson Principles of Bacteriology, Virology and Immunity*, 8th ed, MT Parker & BI Duerden, Eds., pp. (256-269). Edward Arnold, ISBN : 0 340 88565 3., London, UK.
- Queenan AM., Bush K. (2007). Carbapenemases : the versatile β -lactamases. *Clinical Microbiology Review*, Vol 20 No.3 pp. (440-458).
- Saha R., Jain S., Kaur IR. (2010). Metallo β lactamase producing *Pseudomonas* species - a major cause of concern among hospital associated urinary tract infection. *J Indian Med Assoc.* Vol 108 No.6 pp. (344-348).
- Sarkar B., Biswas D., Prasad R. (2006). A clinicomicrobiological study on the importance of *Pseudomonas* in nosocomially infected ICU patients with special reference to metallo β lactamases production. *Indian J Pathol Microbiol.* Vol 49 pp. (44-48).
- Soughakoff W., Goussard S., Courvalin P. (1988) TEM-3- β -lactamases which hydrolyzes broad spectrum cephalosporins, is derived from the TEM-2 penicillinases by two amino acid substitutions. *FEMS Microbiol Lett.* Vol.56 pp. (343-348).
- Størenburg E., Mack D. (2003). Extended-spectrum beta-lactamases: Implications for the clinical microbiology laboratory, therapy, and infection control. *J Infect* Vol 47 pp. (273-295).
- Sugino Y., Iinuma Y., Nada T., Tawada Y., Amano H., Nakamura T., Hasegawa Y., Shimokata K., Shibata N., Arkawa Y. (2001). Antimicrobial activities and mechanism of carbapenem resistance in clinical isolates of carbapenem resistant *P. aeruginosa* and *Acinetobacter* spp. *J Jpn. Assoc. Infect. Dis.* Vol 75 pp. (662-670).
- Thomson K. S. (2001). Controversies about Extended-Spectrum and AmpC Beta-Lactamases. *Emerging Infectious Diseases* Vol 7 No.2 pp. (333-336).
- Toleman MA., Vinodh H., Sekar U., Kamat V., Walsh TR. (2007). blaVIM-2 harboring integrons isolated in India, Russia, and the United States arise from an Ancestral

- Class 1 integron predating the formation of the 3' conserved sequence. *Antimicrob Agents & Chemother* Vol 51 No.7 pp. (2636-2638).
- Tzouvelekis L S., Bonomo R A. (1999). SHV-type beta-lactamases. *Curr. Pharm Des.* Vol 5 pp. (847-864).
- Walsh, T. R., Bolmstrom A., Qwarnstrom A., Gales A. (2002). Evaluation of a new Etest for detecting metallo-lactamases in routine clinical testing. *J. Clin. Microbiol.* Vol 40 pp. (2755-2759).
- Washington CW Jr., Stephen DA., Williams MJ., Elmer WK., Gary WP., Paul CS., Gail LW. (2006). Antimicrobial Susceptibility Testing chapter 17 In *Koneman's Colour Atlas and Textbook of Diagnostic Microbiology*, 6th ed, pp. (945-1021) Lippincott Williams & Wilkins, ISBN : 10: 0-7817-3014-7., Philadelphia PA, USA.
- Watanabe M., Iyobe S., Inoue M., Mitsuhashi S. (1991) Transferable imipenem resistance in *P. aeruginosa*. *Antimicrob Agent Chemother* . Vol 35 pp. (147-151).
- Wayne PA. (2008). Performance standards for antimicrobial susceptibility testing; 18th informational supplement. *Clin Lab Standards Inst.* M100-S18.
- Yagi T., Wachino J., Kurokawa H., Suzuki S., et al. (2005). Practical methods using boronic acid compounds for identification of class C β -lactamase producing *Klebsiella pneumoniae* and *Escherichia coli*. *J of Clin Microbiol.* Vol 43 No.6 pp. (2551-2558).
- Yong D., Lee K., Yum J H., Shin H B., Rossolini F., Chong Y. (2002) Imipenem – EDTA disk method for differentiation of metallo-beta-lactamases producing clinical isolates of *Pseudomonas* spp and *Acinetobacter* spp. *J Clin Microbiol* . Vol 40 pp. (3798 –3801).

IntechOpen



Infection Control - Updates

Edited by Dr. Christopher Sudhakar

ISBN 978-953-51-0055-3

Hard cover, 198 pages

Publisher InTech

Published online 22, February, 2012

Published in print edition February, 2012

Health care associated infection is coupled with significant morbidity and mortality. Prevention and control of infection is indispensable part of health care delivery system. Knowledge of Preventing HAI can help health care providers to make informed and therapeutic decisions thereby prevent or reduce these infections. Infection control is continuously evolving science that is constantly being updated and enhanced. The book will be very useful for all health care professionals to combat with health care associated infections.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Silpi Basak, Ruchita O. Attal and Monali Rajurkar (2012). Pseudomonas Aeruginosa and Newer β -Lactamases: An Emerging Resistance Threat, Infection Control - Updates, Dr. Christopher Sudhakar (Ed.), ISBN: 978-953-51-0055-3, InTech, Available from: <http://www.intechopen.com/books/infection-control-updates/pseudomonas-aeruginosa-and-newer-lactamases-an-emerging-resistance-threat>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen